Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$0.94
-2.6%
$1.17
$0.84
▼
$2.01
$640.37M0.6218.23 million shs9.31 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
-2.60%-5.48%-19.50%-38.44%-15.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$0.94
-2.6%
$1.17
$0.84
▼
$2.01
$640.37M0.6218.23 million shs9.31 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
-2.60%-5.48%-19.50%-38.44%-15.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Corporation stock logo
GERN
Geron
2.33
Hold$3.75298.13% Upside

Current Analyst Ratings Breakdown

Latest GERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Geron Corporation stock logo
GERN
Geron
UpgradeSell (E+) ➝ Sell (D-)
10/28/2026
Geron Corporation stock logo
GERN
Geron
Lower Price TargetOutperform$5.00
10/28/2026
Geron Corporation stock logo
GERN
Geron
Lower Price TargetBuy$4.00 ➝ $2.50
10/21/2026
Geron Corporation stock logo
GERN
Geron
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Corporation stock logo
GERN
Geron
$183.88M3.30N/AN/A$0.35 per share2.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Corporation stock logo
GERN
Geron
-$83.50M-$0.08N/A7.85N/A-23.04%-16.29%-6.82%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Corporation stock logo
GERN
Geron
0.53
6.31
4.61

Institutional Ownership

CompanyInstitutional Ownership
Geron Corporation stock logo
GERN
Geron
73.71%

Insider Ownership

CompanyInsider Ownership
Geron Corporation stock logo
GERN
Geron
1.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Corporation stock logo
GERN
Geron
258644.24 million633.22 millionOptionable

Recent News About These Companies

Geron Earnings Call Highlights RYTELO Growth and Expansion
Geron stock eyes Europe expansion after RYTELO update
Geron: 3 Key Takeaways for Long-Term Investors
Geron Corp (GERN) Q3 2026 Earnings Call Transcript
Geron swings to profits in Q3 on strong Rytelo growth
Geron Q3 Earnings Call Highlights
Geron (GERN) Reports Break-Even Earnings for Q3
Geron Q3 2026 Earnings Call Transcript
Geron: Opportunity Builds Even As Struggles Continue

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$0.94 -0.03 (-2.60%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$0.97 +0.03 (+2.98%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.